RMTG (Regenerative Medical Technology Group) Current Ratio: 0.04 (As of Mar. 2026)— 20% Below Median
What is Regenerative Medical Technology Group Current Ratio?
Regenerative Medical Technology GroupRMTG +11.70% Current Ratio is 0.04 as of Mar. 2026, which is 20% below its 10-year median of 0.05. The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 98.8% on this metric.
Regenerative Medical Technology Group has a current ratio of 0.04. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Regenerative Medical Technology Group has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
RMTG's Current Ratio is ranked worse than 98.8% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs RMTG: 0.04
Regenerative Medical Technology Group (OTCPK:RMTG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Regenerative Medical Technology Group Current Ratio Related Terms
Regenerative Medical Technology Group Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group Current Ratio Chart
RMTG vs PTIX, CERO, EMMA: Current Ratio Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group Current Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a Current Ratio of 0.04 as of Mar. 2026. This is 20% below median its historical median of 0.05. Over the past decade, Regenerative Medical Technology Group's Current Ratio has ranged from 0.01 to 9.39. According to the industry distribution chart, Regenerative Medical Technology Group ranks #1395 out of 1412 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Regenerative Medical Technology Group's Current Ratio too high?
Regenerative Medical Technology Group's current Current Ratio of 0.04 is 20% below median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 9.39. The Biotechnology industry median Current Ratio is 3.89. Regenerative Medical Technology Group's value of 0.04 is 99% below this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #1395 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's Current Ratio compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #1395 out of 1412 companies for Current Ratio. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median Current Ratio is 3.89. Regenerative Medical Technology Group's value of 0.04 is 99% below this benchmark. Historically, Regenerative Medical Technology Group's own Current Ratio has ranged from 0.01 to 9.39 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 3.89, Regenerative Medical Technology Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current Current Ratio of 0.04 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current Current Ratio is 0.04, which is 20% below median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.06, compared to a current price of $0.05 — trading 15.9% below its estimated fair value. The current Current Ratio is 0.04, which is 20% below median its 10-year median of 0.05 and 99% below the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Current Ratio is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 